What is the first-line treatment for chronic phase chronic myelogenous leukemia (CP-CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


For low-risk patients, any of the following may be used for first-line treatment [2, 3, 15, 18] :

For intermediate- or high-risk patients, bosutinib, dasatinib or nilotinib is preferred over imatinib; dosages are the same as for low-risk patients. [2, 3, 15, 18] Note that allogeneic hematopoietic stem cell transplantation (HCT) is not recommended as first-line treatment for CP-CML.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!